Details for Patent: 10,039,754
✉ Email this page to a colleague
Which drugs does patent 10,039,754 protect, and when does it expire?
Patent 10,039,754 protects MAVYRET and is included in two NDAs.
Protection for MAVYRET has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has two hundred and seventy-two patent family members in forty-five countries.
Summary for Patent: 10,039,754
Title: | Anti-viral compounds |
Abstract: | Compounds effective in inhibiting replication of Hepatitis C virus ("HCV") are described. This invention also relates to processes of making such compounds, compositions comprising such compounds, and methods of using such compounds to treat HCV infection. |
Inventor(s): | Bellizzi; Mary E. (Missoula, MT), Betebenner; David A. (Grayslake, IL), Califano; Jean-Christophe C. (Whitefish Bay, WI), Carroll; William A. (Evanston, IL), Caspi; Daniel D. (Evanston, IL), DeGoey; David A. (Salem, WI), Donner; Pamela L. (Mundelein, IL), Flentge; Charles A. (Pittsburgh, PA), Gao; Yi (Vernon Hills, IL), Hutchins; Charles W. (Green Oaks, IL), Hutchinson; Douglas K. (Newton, CT), Jinkerson; Tammie K. (Pleasant Prairie, WI), Kati; Warren M. (Gurnee, IL), Keddy; Ryan G. (Beach Park, CA), Krueger; Allan C. (Gurnee, IL), Li; Wenke (Gurnee, IL), Liu; Dachun (Vernon Hills, IL), Maring; Clarence J. (Palatine, IL), Matulenko; Mark A. (Libertyville, IL), Motter; Christopher E. (Oak Creek, WI), Nelson; Lissa T. (Highland Park, IL), Patel; Sachin V. (Round Lake, IL), Pratt; John K. (Kenosha, WI), Randolph; John T. (Libertyville, IL), Rockway; Todd W. (Grayslake, IL), Sarris; Kathy (Mundelein, IL), Tufano; Michael D. (Chicago, IL), Wagaw; Seble H. (Lake Bluff, IL), Wagner; Rolf (Antioch, IL), Woller; Kevin R. (Antioch, IL) |
Assignee: | AbbVie Inc. (North Chicago, IL) |
Application Number: | 15/431,069 |
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 10,039,754
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Abbvie | MAVYRET | glecaprevir; pibrentasvir | PELLETS;ORAL | 215110-001 | Jun 10, 2021 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
Abbvie | MAVYRET | glecaprevir; pibrentasvir | TABLET;ORAL | 209394-001 | Aug 3, 2017 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,039,754
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Argentina | 077060 | ⤷ Try a Trial | |||
Argentina | 083240 | ⤷ Try a Trial | |||
Argentina | 083398 | ⤷ Try a Trial | |||
Argentina | 092505 | ⤷ Try a Trial | |||
Argentina | 094816 | ⤷ Try a Trial | |||
Australia | 2010258769 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |